This page shows the latest pancreatic cancer news and features for those working in and with pharma, biotech and healthcare.
In July 2020, Merus received an orphan drug designation from the US Food and Drug Administration (FDA) for its first-in-class bispecific antibody zenocutuzumab for the treatment of pancreatic cancer. ... In early clinical trials, zenocutuzumab
Early detection – particularly for hard-to-treat conditions like ovarian and pancreatic cancer – has the potential to save many lives,” said Simon Stevens, chief executive of the NHS. ... This promising blood test could therefore be a game-changer
The approval was based on results from the phase 3 POLO trial of Lynparza (olaparib) in advanced pancreatic cancer patients whose tumours carry BRCA mutations. ... In the POLO trial, Lynparza nearly doubled median progression-free survival versus placebo
The patient population included 160 people with locally advanced or metastatic pancreatic cancer that had progressed during or after one line of chemotherapy. ... It also carries poor survival rates – less than 7% of patients are still alive five years
Product sales were up 12% to $23.57bn for the full-year, driven by cancer products and turnover in emerging markets, although there was a bit of a slowdown to 8% ... Imfinzi meanwhile grew 62% to $424m, helped by increased use as maintenance therapy for
Weight-loss drug linked to increased risk of cancer. Eisai has moved swiftly to comply with an FDA request to pull its obesity drug Belviq off the market after it was ... In 2010, the FDA rejected the first marketing application for the drug, filed by
More from news
Approximately 29 fully matching, plus 119 partially matching documents found.
That includes potential new approvals for PARP inhibitor Lynparza in prostate and pancreatic cancer to extend its existing use in ovarian and breast cancer. ... The company’s biggest play last year was licensing Daiichi Sankyo’s cancer candidate
the only PARP inhibitor with positive phase 3 results in four different cancer types (ovarian, breast, pancreatic and prostate). ... First we had ovarian cancer, then breast cancer, and our next steps will be for metastatic pancreatic cancer and men with
13 new targeted medicines that block the growth and spread of cancer by interfering with specific molecular targets. ... and ovarian cancer, and some tumours such as pancreatic and prostate cancers have proved resistant to current immunotherapies.
Mr Whitley took part in a pancreatic cancer drug trial in 2011.
triple-negative breast cancer (TNBC), small-cell lung cancer (SCLC), non-small-cell lung cancer (NSCLC) and pancreatic cancer. . ... Licence. 358. AstraZeneca/ TerSera Therapeutics. Zoladex, goserelin acetate implant for prostate, breast cancer,
More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.
This is even more pertinent with the recent changes to the Cancer Drugs Fund, which I strongly hope will enable patients with myeloma and metastatic pancreatic cancer to continue to be
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
introduction of multiple localized and targeted therapies in recent years, 2 more than 30, 000 patients succumbed to liver cancer.1 The situation for pancreatic cancer is even more urgent. ... Accessed March 5, 2019. Balaban EP, Mangu PB, Yee NS. Locally
The Porterhouse team has also raised funds for Pancreatic Cancer UK (); the ovarian cancer support charity Ovacome (); and the disability sports club SportsAble (). We are delighted to reveal that our team
This year’s theme focused on securing access to optimal cancer care – a poignant topic and one that resonates across the healthcare sector, impacting patients in all walks of life. ... Ipsen Group developed an eye-catching attraction to offset this
44 (0) 118 913 9100. Address:. 4 Windsor Square. Silver Street. Reading. RG1 2TH. United Kingdom.
5]. In spite of these statistics, funding for pancreatic cancer and disease awareness are low. ... Indeed, in one analysis, only 75% of patients with localised pancreatic cancer underwent surgical evaluation.
More from PMHub
Approximately 3 fully matching, plus 5 partially matching documents found.
Valid Insight is an award-winning pharmaceutical global market access consultancy....